Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Abstract

In the largest sample used thus for, our study found that approximately 10% of Chinese NSCLC patients had <i>KRAS</i> mutations. Of these, nearly 30% harbored the <i>KRAS G12C</i> mutation subtype, which was most common in male smokers. The <i>KRAS G12C</i> mutation is a biomarker of poor prognosis in Chinese NSCLC patients, which could potentially be improved by <i>G12C</i>-specific inhibitors in the future.(296 words).